| Literature DB >> 16511425 |
Bénédicte Roquebert1, Isabelle Malet, Marc Wirden, Roland Tubiana, Marc-Antoine Valantin, Anne Simon, Christine Katlama, Gilles Peytavin, Vincent Calvez, Anne-Geneviève Marcelin.
Abstract
We investigated, in the protease and GAG cleavage sites, the role of minority populations on the evolution of resistance to a subsequent boosted protease inhibitor (PI) regimen after a first failure to nelfinavir. Two pathways were observed: the addition of mutations to a currently dominant genotype when minority variants are not shown, or the emergence of a minority variant as a dominant strain. These minor species, not detected by standard genotype, may influence PI susceptibility.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16511425 DOI: 10.1097/01.aids.0000202650.03279.69
Source DB: PubMed Journal: AIDS ISSN: 0269-9370 Impact factor: 4.177